Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
00:36:48 EST Thu 12 Dec 2024
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:DTCFF - DEFENCE THERAPEUTICS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
DTCFF - Qnot subscribed0.41346    1.821  0.40Dec 09Dec 0215 min RT 2¢

Recent Trades - All 0 today
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-12-02 19:01U:DTCFFNews ReleaseDefence Provides Update on Delivery of AGSM Proxy Materials
2024-11-29 18:01U:DTCFFNews ReleaseDefence's Proprietary Accum Technology Ready to License to Companies Developing Antibody Drug Conjugates (ADC)
2024-11-25 03:17U:DTCFFNews ReleaseDefence Announces Dr. Maxime Parisotto as CSO, Director of Science and Business Development
2024-11-22 19:01U:DTCFFNews ReleaseDefence Announces Closing of Securities for Debenture Financing
2024-11-14 19:31U:DTCFFNews ReleaseDefence Therapeutics Announces Securities for Debenture Financing
2024-11-13 03:16U:DTCFFNews ReleaseDefence Announces Radiopharmaceutical Expert Svetlana Selivanova Joins Board of Directors
2024-11-04 18:17U:DTCFFNews ReleaseDefence Announces Extension of Private Placement, Continues Development of Its Radiopharmaceuticals and ADC Programs
2024-10-30 18:01U:DTCFFNews ReleaseDefence Therapeutics Completes 1st Tranche of Financing
2024-09-27 07:01U:DTCFFNews ReleaseDefence's Corporate Updates, Arranges Financing
2024-08-30 20:01U:DTCFFNews ReleaseDefence Appoints New Interim Chief Executive Officer
2024-08-19 09:28U:DTCFFNews ReleaseDefence Investigates the Application of the Accum Hydrogel Technology to Deliver GLP-1 in Order to Increase the Treatment Efficacy of Diabetes and Weight Loss
2024-08-13 03:16U:DTCFFNews ReleaseDefence Therapeutics Collaboration Agreement with Orano to Develop the Next Generation of Targeted Radio-Immunotherapy for Cancer Advances
2024-07-24 03:16U:DTCFFNews ReleaseDefence Therapeutics Granted CNRI-H from the Canadian Nuclear Laboratories to Accelerate the Development of Its Radio-Immuno-Conjugates Program
2024-07-08 03:16U:DTCFFNews ReleaseDefence Receives No Objection Letter from Health Canada for Phase I Trial of Its ACCUM-002 (AccuTOX) as an Anti-Cancer Molecule in Patients with Melanoma
2024-06-28 17:09U:DTCFFNews ReleaseDefence's AccuTOX Boosts and Synergizes with Immune Checkpoint Inhibitors
2024-06-25 03:16U:DTCFFNews ReleaseDefence's ARM-X Anti-Cancer Vaccine Inhibits Growth of Pre-Established Ovarian Cancer Resulting in Complete Responses in Treated Animals
2024-06-17 03:16U:DTCFFNews ReleaseDefence's Chief Scientific Officer Dr. Moutih Rafei Discusses the Accum Platform for Cancer Treatments on Money Talk Radio with Ellis Martin
2024-06-12 05:31U:DTCFFNews ReleaseEllis Martin Report: Defence Therapeutics Inc. (DTCFF) Dr. Moutih Rafei-Developing Vaccines and Platform Technologies for the Treatment of Cancer
2024-06-10 03:16U:DTCFFNews ReleaseDefence to Participate in 2024 Society of Nuclear Medicine and Molecular Imaging Annual Meeting in Toronto on June 11, 2024
2024-06-06 03:16U:DTCFFNews ReleaseDefence's AccuTOX Published in the Prestigious Journal of Translational Medicine Its Peer Study with Preclinical Data on AccuTOX as an Anti-Cancer Molecule